Table 1.
Demographic variables at baseline in each group.
| Characteristics | Levosimendan (n=19) | Dobutamine (n=19) | P-value |
|---|---|---|---|
| Age(years) | 55.4±17.5 | 50.2±13.6 | 0.313 |
| Male (n,%) | 13 (68.4) | 11 (57.9) | 0.501 |
| APCHEII | 18.4±4.5 | 19.5±4.3 | 0.446 |
| SOFA | 4.2±1.8 | 4.3±2.6 | 0.891 |
| Type of infection (n,%) | |||
| Pneumonia | 8 (42.1.%) | 10 (52.6%) | 0.516 |
| Peritonitis | 5 (26.3%) | 4 (21.1%) | 0.703 |
| CRBSI | 4 (21.1%) | 2 (10.5%) | 0.374 |
| Urinary tract infection | 2 (10.5%) | 3 (15.8%) | 0.631 |
| Days on MV | 6.9±5.5 | 7.2±5.3 | 0.865 |
| Length of stay in ICU(days) | 12.6±10.1 | 13.3±10.5 | 0.835 |
| Length of stay in hospital(days) | 20.4±21.5 | 22.5±23.1 | 0.773 |
| 28-day mortality% (n) | 31.6% (6) | 36.8% (7) | 0.732 |
yr – years; APACHE II – acute physiology and chronic health evaluation; SOFA – sequential organ failure assessment; CRBSI – catheter related bloodstream infection; MV – mechanical ventilation; ICU – intensive care unit.